FDA Eyes Testosterone Expansion as GLP-1 Rivals Emerge
The FDA is examining expanded testosterone therapy approvals for libido while GLP-1's grip on obesity treatment faces a scientific challenge from its own pioneers. Researchers now argue GIP-glucagon dual targeting may match GLP-1 efficacy with better tolerability. Kailera Therapeutics raised $625 million in what is